IPP Bureau
Bristol Myers Squibb’s application for Opdivo plus chemotherapy receives USFDA priority review
By IPP Bureau - March 01, 2022
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
Novavax UK Phase 3 trial demonstrates protection from Covid-19 over six-month period
By IPP Bureau - March 01, 2022
High level of vaccine efficacy maintained over a 6-month period of surveillance
Boehringer Ingelheim partners with Lifebit to capture health data
By IPP Bureau - March 01, 2022
This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine
AstraZeneca and Neurimmune enter licencing agreement to develop and commercialise NI006
By IPP Bureau - March 01, 2022
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
Innovent Biologics and AnHeart Therapeutics receive NMPA breakthrough designation for taletrectinib
By IPP Bureau - March 01, 2022
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Bruker releases CCS-Enabled TIMScore and TIMS DIA-NN 4D Proteomics Software
By IPP Bureau - March 01, 2022
Innovative TIMScore for dda-PASEF and dia-PASEF libraries, combined with TIMS DIA-NN identifies 9000 protein groups from 200 ng K562 lysate in just 35 min gradient
IDT Biologika collaborates with Exothera to push forward the scale-up of viral vaccines
By IPP Bureau - March 01, 2022
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Synapse Medicine raises US $ 28 million to scale its medication reconciliation platform
By IPP Bureau - March 01, 2022
The company, already scaling across Europe, plans to accelerate the deployment of its medication reconciliation platform in the United States
South Korea's OCI acquires 11% stake in Bukwang Pharmaceutical
By IPP Bureau - March 01, 2022
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Lupin launches Sevelamer Hydrochloride tablets in the United States
By IPP Bureau - March 01, 2022
Sevelamer Hydrochloride tablets, 800 mg is a generic equivalent of Renagel tablets, 800 mg
Thermo Fisher Scientific extends partnership with Symphogen to support biopharma
By IPP Bureau - March 01, 2022
Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments
USFDA approves CITI Biopharma’s Vonjo
By IPP Bureau - March 01, 2022
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
Biocon Biologics acquires Viatris’ biosimilar assets for up to US $ 3.3 billion
By IPP Bureau - February 28, 2022
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
China’s NMPA accepts supplemental NDA for Carteyva
By IPP Bureau - February 28, 2022
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
Unichem receives ANDA approval for bipolar disorder drug
By IPP Bureau - February 28, 2022
Divalproex Sodium Extended-Release tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, as monotherapy and adjunctive therapy and prophylaxis of migraine headaches
